Who is the manufacturer of QSM software, QSMetric?

Medimagemetric, LLC filed the 510(k) submission for QSM software, QSMetric (K210415).

What is the FDA product code for QSM software, QSMetric?

LNH. It is classified under 21 CFR 892.1000 as a Class 2 device in the Radiology panel.

What is the regulatory pathway for QSM software, QSMetric?

510(k) clearance (submission type: Traditional).

What are the predicate devices for QSM software, QSMetric?

SWIp from PHILIPS MEDICAL SYSTEMS NEDERLAND B.V. (K131241).

Who can help prepare an FDA 510(k) submission like QSM software, QSMetric?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

QSM software, QSMetric

K210415 · Medimagemetric, LLC · LNH · Jul 22, 2021 · Radiology

Device Facts

Record ID	K210415
Device Name	QSM software, QSMetric
Applicant	Medimagemetric, LLC
Product Code	LNH · Radiology
Decision Date	Jul 22, 2021
Decision	SESE
Submission Type	Traditional
Regulation	21 CFR 892.1000
Device Class	Class 2
Attributes	Software as a Medical Device

Intended Use

QSM software (QSMetric™) is intended for use in the post-acquisition image enhancement of 3D MR images of the brain acquired using a gradient-echo sequence at 1.5T, 3T and 7T field strengths. QSM uses phase information to enhance contrast between tissues presenting magnetic susceptibility differences, such as deoxygenated blood, iron or calcium deposits. When used in combination with other clinical information, QSM may aid the qualified physicians in visualizing tissue structures with magnetic susceptibility contrasts and measuring their susceptibility values.

Device Story

QSM software (QSMetric) processes 3D gradient-echo MR brain images (magnitude/phase or real/imaginary data) to generate tissue magnetic susceptibility contrast maps. Operates as post-processing solution integrated with third-party DICOM viewers. Workflow: input raw MR data; software performs phase unwrapping, background field removal, and dipole phase modeling; output is a susceptibility contrast map. Used in radiological services by physicians to visualize structures like deoxygenated blood, iron, or calcium deposits. Enhances diagnostic capability by providing quantitative susceptibility values alongside standard MR images; aids in neurological pathology assessment.

Clinical Evidence

No clinical studies required. Evidence based on non-clinical verification and validation testing, including simulated use and clinical user needs testing. All predefined acceptance criteria met across multiple scanner manufacturers, demonstrating acceptable image quality and substantial equivalence to predicate.

Technological Characteristics

Software-based image post-processing for MRI. Inputs: 3D gradient-echo magnitude/phase or real/imaginary images. Processing: phase unwrapping, background field removal, dipole phase modeling. Output: tissue susceptibility contrast map. Compatible with 1.5T, 3T, 7T MRI systems from GE, Philips, Siemens, and United Imaging. Operates as standalone software integrated with DICOM viewers.

Indications for Use

Indicated for post-acquisition enhancement of 3D brain MR images (gradient-echo, 1.5T/3T/7T) to visualize and measure magnetic susceptibility contrasts in tissues (e.g., deoxygenated blood, iron, calcium). For use by qualified physicians as an adjunct to other clinical information.

Regulatory Classification

Identification

A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).

Special Controls

*Classification.* Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.

Predicate Devices

SWIp from PHILIPS MEDICAL SYSTEMS NEDERLAND B.V. (K131241)

Related Devices

K203279 — Veuron-Brain-mN1 · Heuron Co., Ltd. · Jul 12, 2022
K173224 — SPIN-SWI · Spintech, Inc. · Feb 23, 2018
K233733 — SyMRI · Syntheticmr AB (Publ.) · Mar 26, 2024
K181093 — SyMRI · Syntheticmr AB · Jun 12, 2018
K210843 — STAGE · Spintech, Inc. · Jun 29, 2021

Submission Summary (Full Text)

{0}------------------------------------------------ July 22, 2021 Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. Medimagemetric LLC % Yi Wang President & CEO 455 Main Street, #7H NEW YORK NY 10044 Re: K210415 Trade/Device Name: QSM software, QSMetric"™ Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: Class II Product Code: LNH Dated: June 21, 2021 Received: June 21, 2021 Dear Yi Wang: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) {1}------------------------------------------------ regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, For Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K210415 Device Name QSM software Indications for Use (Describe) QSM software (QSMetric™) is intended for use in the post-acquisition image enhancement of 3D MR images of the brain acquired using a gradient-echo sequence at 1.5T, 3T and 7T field strengths. QSM uses phase information to enhance contrast between tissues presenting magnetic susceptibility differences, such as deoxygenated blood, iron or calcium deposits. When used in combination with other clinical information, QSM may aid the qualified physicians in visualizing tissue structures with magnetic susceptibility contrasts and measuring their susceptibility values. | Type of Use (Select one or both, as applicable) | | |-------------------------------------------------|--------------------------------------------------| | X Prescription Use (Part 21 CFR 801 Subpart D) | __ Over-The-Counter Use (21 CFR 801 Subpart C) | #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ K210415 ## 510(k) Summary (21 CFR 807.92) This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92 ## General information | Submitter: | Medimagemetric LLC | | |--------------|------------------------------|--| | | 171 Floral Ave | | | | Johnson City, New York 13790 | | | Contact | Yi Wang | | | | Tel: 929.314.2988 | | | Prepared on: | 2/8/2021 | | ## Device name and classification | Trade name: | QSMetric™ | |-----------------|--------------------------------------------------------------------------| | Common name: | Radiological image processing software | | Classification: | Magnetic resonance diagnostic device (21 CFR 892.1000, Product code LNH) | ## Legally marketed device of substantial equivalence (SE) - predicate device SWIp from PHILIPS MEDICAL SYSTEMS NEDERLAND B.V. (595 MINER RD, Cleveland, OH 44143), cleared for US commercialization via K131241 on 8/30/2013. ## Device description The product QSMetric™, also referred to as QSM software, postprocesses gradient echo magnetic resonance (MR) images to depict tissue magnetic susceptibility contrast (local difference). Tissue susceptibility contrast sources include highly paramagnetic iron presented in deoxyhemoglobin, ferritin and hemosiderin, and diamagnetic calcification. Susceptibility contrast material of tissue in the MR scanner generates its own magnetic field according to the convolution law in magnetism. This tissue field with its dispersion in space causes MR image signal magnitude loss, creating contrasts in magnitude images. Therefore, the magnitude image is commonly used to indicate the presence of nearby tissue susceptibility contrast. In addition to magnitude images, a gradient echo MR scan results in also phase images. The tissue field causes MR image signal phase accrual, creating contrasts in phase images. The phase image of gradient echo MR data is the product of echo time and tissue field. Accordingly, the phase images from a gradient echo MR scan is processed using QSM to enhance the depiction of tissue susceptibility contrasts. QSM software works in conjunction with any FDA cleared third-party DICOM viewer as an image postprocessing solution in radiological service. ## Intended use QSM software (QSMetric ™ ) is intended for use in the post-acquisition image enhancement of 3D MR images of the brain acquired using a gradient-echo sequence at 1.5T, 3T and 7T field strengths. QSM uses phase information to enhance contrast between tissues presenting magnetic {4}------------------------------------------------ susceptibility differences, such as deoxygenated blood, iron or calcium deposits. When used in combination with other clinical information, QSM may aid the qualified physicians in visualizing tissue structures with magnetic susceptibility contrasts and measuring their susceptibility values. Technological characteristics: substantial equivalence between QSM and predicate SWIp QSM's fundamental technological characteristics are substantially equivalent to those of the predicate device SWIp (K131241) as described in this submission. The substantial equivalence between QSM and SWIp are noted in the following table. | Features specifications | Subject device | Predicate device | QSM- SWIp SE | |----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------| | Regulation name | Magnetic resonance diagnostic device | Magnetic resonance diagnostic device | Yes | | Prescription use | Yes | Yes | Yes | | Intended use | QSM software (QSMetricTM ) is intended for use in the post-acquisition image enhancement of 3D MR images of the brain acquired using a gradient-echo sequence at 1.5T, 3T and 7T field strengths. QSM uses phase information to enhance contrast between tissues presenting magnetic susceptibility differences, such as deoxygenated blood, iron or calcium deposits. When used in combination with other clinical information, QSM may aid the qualified physicians in visualizing tissue structures with magnetic susceptibility contrasts and measuring their susceptibility values. | SWIp is a software option intended for use on Achieva and Ingenia 1.5T & 3.0T MR Systems. It's indicated for magnetic resonance imaging of the brain. SWIp is a technique using phase information to enhance contrast between tissues presenting susceptibility differences, such as deoxygenated blood or some mineral deposits (e.g. calcium deposits). Due to this contrast enhancement, SWIp images are sensitive for structures containing venous blood such as cerebral venous vasculature. When used in combination with other clinical information, SWIp may help the expert radiologist in the diagnosis of various neurological pathologies. | Yes | | MRI system | MRI systems from General Electric, Philips, Siemens, and United Imaging | 3.0T and 1.5T, Achieva and Ingenia MRI systems from Philips | Yes | | Input data | 3D gradient echo magnitude and phase images, or real and imaginary images | gradient echo magnitude and phase images | Yes | | Phase processing | Phase unwrapping Background field removal | Phase unwrapping Background field removal | Yes | | | Dipole phase modeling to measure susceptibility contrasts with phase and magnitude info | Spectral phase modeling to enhance susceptibility contrasts with phase and magnitude info | | | User interface | Automated postprocessing | Automated postprocessing | Yes | | Output | Tissue susceptibility contrast map | Images with enhanced contrasts between tissues with susceptibility differences | Yes | {5}------------------------------------------------ ## SE-Nonclinical performance data The following design control, risk management and quality assurance methodologies were utilized to develop QSM software: - Quality policy and system establishment - Software requirements specification review ● - Software design review ● - Risk management ● - Traceability analysis ● - Verification testing at unit and integration levels ● - Validation testing on simulated use and nonclinical use. . Software documentation for Moderate Level of Concern software per the FDA's "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" issued on May 11, 2005, is also included in this premarket notification submission. The QSM software has been tested in accordance with Medimagemetric's verification and validation procedures. All predefined acceptance criteria for the engineering performance testing were met for all test cases across different scanner manufacturers. The results from the nonclinical testing performed on the QSM software demonstrate that the QSM software produces results consistently according to its intended use and is substantially equivalent to combining information from SWIp both magnitude and phase images output from the predicate device. ## SE-Clinical performance data The subject device of this premarket notification, QSM software, did not require clinical studies to support substantial equivalence to the predicate device. All predefined acceptance criteria for clinical validation testing, including clinical user needs testing, as a part of the QSM performance validation testing efforts, were met across all test cases. The results of the clinical validation related testing performed on the QSM software demonstrate that output image quality are acceptable, all clinical user needs are met, and QSM is substantially equivalent to combining information from SWIp both magnitude and phase images output from the predicate device. ## Conclusions from nonclinical and clinical performance data The subject device and the predicate device are substantially equivalent, with respect to intended use, instructions for use, design features, technological characteristics, manufacturing methods, {6}------------------------------------------------ Image /page/6/Picture/0 description: The image shows the logo for MedImageMetric. The logo consists of the acronym "MIM" in a red square, followed by the words "MedImageMetric" in blue and black. The word "MedImage" is in blue, and the word "Metric" is in black and red. performance criteria, safety, and effectiveness. The subject device is substantially equivalent to the predicate device (K131241) noted herein.